New Jersey 2026-2027 Regular Session

New Jersey Senate Bill S3165

Introduced
1/13/26  

Caption

Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

Impact

The implementation of S3165 is expected to enhance access to long-acting injectable antipsychotic drugs for individuals receiving care in inpatient facilities, likely resulting in improved health outcomes and greater adherence to prescribed treatment regimens. The bill seeks to address potential barriers to accessing these vital medications, which can reduce the frequency of hospitalizations and the need for further medical interventions. By aligning inpatient reimbursement rates with outpatient rates, the legislation aims to make long-acting injectable antipsychotic drugs more accessible to patients during critical periods of care.

Summary

Senate Bill S3165, sponsored by Senator Nicholas P. Scutari, mandates that NJ FamilyCare provide reimbursement for long-acting injectable antipsychotic drugs administered in inpatient settings at the same rate as the outpatient reimbursement rate. This change is aimed at ensuring that inpatient providers receive compensation that more accurately reflects the cost of these medications, which are essential for treating severe mental health conditions such as schizophrenia and bipolar disorder. The bill is a response to existing reimbursement systems that fail to adequately account for the high expenses of medications classified under Diagnostic Related Groups (DRGs).

Contention

Notable points of contention surrounding S3165 may stem from concerns about the financial implications for healthcare providers and the Medicaid program. While the bill aims to improve patient care and reduce hospital readmission rates, critics may argue that the changes in reimbursement policies could strain hospital budgets or lead to unintended consequences within the broader healthcare system. The need for the Commissioner of Human Services to seek potential amendments or waivers for federal financial support further indicates the complexity and challenges associated with implementing the proposed changes.

Companion Bills

NJ S3837

Carry Over Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

NJ A5409

Carry Over Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

NJ A2120

Same As Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

Similar Bills

NJ A2120

Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

AZ SB1672

AHCCCS; antipsychotic drugs; authorization

CA SB820

Inmates: mental health.

OK HB2801

Antipsychotic drugs; vendor drug program; Oklahoma Health Care Authority; prior authorized; disorders; prior authorization; effective date.

OK HB2801

Antipsychotic drugs; vendor drug program; Oklahoma Health Care Authority; prior authorized; disorders; prior authorization; effective date.

MO HB2512

Creates provisions relating to humane access to emergency psychiatric treatment

CA AB2275

Mental health diversion.

AZ SB1720

Clozapine; access; treatment protocols